Bioventus Inc.
Rank #58ValueBVS · Nasdaq · Healthcare
Bioventus Inc. (BVS) — Rank #58 by gross profitability (GP/assets 0.58) · ROE 10.0% · Piotroski F-Score 8 / 9.
As-of 2026-09-15 · CIK 0001665988 · all metrics point-in-time as of the filing date.
About
Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally.
Show moreShow less
The company's product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides neXus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; BoneScalpel Access, for bone removal with visualization; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company's restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system. The company sells its products to healthcare institutions, physicians, patients, distributors and dealers. Bioventus Inc.
was founded in 2011 and is headquartered in Durham, North Carolina.
- Industry
- Medical Devices
- Sector
- Healthcare
- State
- DE
- Filer Category
- Accelerated filerEmerging growth company
- Fiscal Year End
- December 31
- Website
- bioventus.com
Financials
Each fiscal year is read as-of that year’s own 10-K filing, so nothing restated after the fact leaks backwards. Line items this filer never tagged are omitted. Hover or tap a badge for the diagnostic behind it.
| Fiscal year end | 2025-12-31filed 2026-03-05 | 2024-12-31filed 2025-03-11 | 2023-12-31filed 2024-03-12 | 2022-12-31filed 2023-03-31 |
|---|---|---|---|---|
| Revenue | 568.1 | 573.3 | 512.3 | 512.1 |
| Revenue growth (YoY) | -0.9% | 11.9% | 0.0% | 18.8% |
| Cost of revenue | 179.9 | 185.1 | 184.2 | 181.0 |
| Gross profit | 388.2 | 388.2 | 328.2 | 331.1 |
| Gross margin | 68.3% | 67.7% | 64.1% | 64.6% |
| Selling, general & administrative | 314.0 | 340.9 | 303.9 | 332.6 |
| Research & development | 12.1 | 13.6 | 13.4 | 25.9 |
| Operating income | 54.0 | (12.0) | (81.7) | (251.0) |
| Operating margin | 9.5% | -2.1% | -16.0% | -49.0% |
| Pre-tax income | 25.7 | (49.1) | (121.1) | (263.9) |
| Income tax expense | (1.6) | (5.3) | 0.1 | (50.5) |
| Net income | 22.7 | (33.5) | (156.2) | (158.7) |
| Net margin | 4.0% | -5.9% | -30.5% | -31.0% |
| EPS (basic) | $0.34 | -$0.52 | -$2.49 | -$2.59 |
| EPS (diluted) | $0.33 | -$0.52 | -$2.49 | -$2.59 |
Figures are as originally filed with the SEC (point-in-time), not restated, so they can differ slightly from sites that show later-restated numbers. Why point-in-time?